SKYE 4.63 Skye Bioscience, Inc.
| Range: | 1.44-19.41 | Vol Avg: | 315540 | Last Div: | 0 | Changes: | 0.4 |
| Beta: | 1.79 | Cap: | 0.14B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Wed Nov 26 2014 | Empoloyees: | 11 | ||
| CUSIP: | 83086J101 | CIK: | 0001516551 | ISIN: | US83086J2006 | Country: | US |
| CEO: | Mr. Punit S. Dhillon B.A. | Website: | https://skyebioscience.com | ||||
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Stock Details
Positive 0.13
Don't Sleep on Skye Bioscience—This Weight Loss Drug Could Soar
Skye Bioscience NASDAQ: SKYE is a micro-cap pharmaceutical company that is striving to bec...
marketbeat.com·Wed Oct 09 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow